Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression

Authors: Wei Jiang, Hong Fan, Cheng Qian, Jianyong Ding, Qun Wang, Xuguang Pang

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

FoxC2 is an epithelial–mesenchymal transition (EMT) regulator which induces metastasis. The purpose of this study is to assess the prognostic value of FoxC2 expression in non-small cell lung cancer (NSCLC), alone or in combination with E-cadherin expression.

Methods

A retrospective study was conducted using immunohistochemistry to investigate FoxC2 and E-cadherin expression in a cohort of 309 patients with surgically resected NSCLCs. The prognostic value of FoxC2 and E-cadherin on overall survival (OS) and recurrence-free survival (RFS) was determined by Kaplan-Meier analysis and Cox proportional hazard models.

Results

High FoxC2 expression was detected in 26.5 % of tumors, and significantly correlated with tobacco use (p = 0.047), adenocarcinoma (p = 0.008) and nodal involvement (p < 0.001). Univariate analysis revealed its association with OS (p = 0.036) and RFS (p = 0.011). By multivariate analysis, high FoxC2 expression lost its significance as an independent predictor of recurrence (p = 0.077), while TNM stage, nodal status and the presence of high FoxC2 and impaired E-cadherin expression retained independent prognostic significance in relation to both OS and RFS. Subset analyses indicated that high FoxC2 expression was significantly associated with disease outcome in node-positive, but not in node-negative patients.

Conclusion

Evaluation of FoxC2 expression, alone or in combination with E-cadherin expression, may help to stratify NSCLC patients for risk of disease progression, pointing to this EMT regulator as a potential prognostic marker.
Literature
1.
2.
Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 2006;81:1021–7.PubMedCrossRef
3.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRef
4.
5.
YilmazM CG, Lehembre F. Distinct mechanisms of tumor invasion andmetas tasis. Trends Mol Med. 2007;13:535–41.CrossRef
6.
Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12:5369–76.PubMedCrossRef
7.
Peinado H, Olmedo D, Cano A. Snail, ZEB, and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.PubMedCrossRef
8.
Alves CC, Carneiro F, Hoefler H, Becker KF. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci. 2009;14:3035–50.CrossRef
9.
Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA. 2007;104:10069–74.PubMedPubMedCentralCrossRef
10.
11.
Nishida N, Mimori K, Yokobori T, Sudo T, Tanaka F, Shibata K, et al. FOXC2 is a novel prognostic factor in <?show [?A3B2 twb=.27w?]?><?show [?A3B2 tlsb=-.11pt?]?>human esophageal squamous cell carcinoma. Ann Surg Oncol. 2011;18:535–42.PubMedCrossRef
12.
Sano H, Leboeuf JP, Novitskiy SV, Seo S, Zaja-Milatovic S, Dikov MM. The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun. 2010;392:201–6.PubMedPubMedCentralCrossRef
13.
Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 2013;73(6):1981–92.PubMedPubMedCentralCrossRef
14.
Jiang W, Pang XG, Wang Q, Shen YX, Chen XK, Xi JJ. Prognostic role of twist, slug, and foxc2 expression in stage Inon-small-cell lung cancer after curative resection. Clin Lung Cancer. 2012;13:280–7.PubMedCrossRef
15.
Zhu J-L, Song Y-X, Wang Z-N, Gao P, Wang M-X, Dong Y-L, et al. The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology. 2013;62:1038–48.PubMedCrossRef
16.
Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826(2):297–311.PubMed
17.
18.
Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4:118–32.PubMedCrossRef
19.
Mortazavi F, An J, Dubinett S, Rettig M. p120-Catenin is transcriptionally downregulated by FOXC2 in non -small cell lung cancer cells. Mol Cancer Res. 2010;8:762–74.PubMedCrossRef
20.
21.
McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res. 2002;8(4):1127–38.PubMed
22.
Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: From molecular mechanisms to clinical application. Clin Cancer Res. 2004;10:3237–48.PubMedCrossRef
23.
Watanabe A, Suzuki H, Yokobori T, Altan B, Kubo N, Araki K, et al. Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis. Cancer Sci. 2013;104(11):1427–32.PubMedCrossRef
Metadata
Title
Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression
Authors
Wei Jiang
Hong Fan
Cheng Qian
Jianyong Ding
Qun Wang
Xuguang Pang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2056-0

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer

Research article

Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany

Research article

Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells

Research article

Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage

Study protocol

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma

Research article

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits